Dr. Reddy's Laboratories

We are excited to welcome Martin MEULDERS, who joins us as Head of Marketing for Consumer Healthcare. Martin is part of our team focusing on our newly acquired global portfolio of Nicotine Replacement Therapy brands from Haleon plc, including the global market-leading brand, Nicotinell. #WeAreDrReddys #GoodHealthCantWait #DrReddysEurope #DrReddysConsumerHealthcare

"The practical training offered in the GROW EV technician course deepened my understanding of electric scooters and motivated me to pursue a career in this sector." As the demand for electric vehicles rises, the GROW Green Jobs initiative enables youth from low-income households to take advantage of opportunities. These demand-led courses equip participants with essential technical and soft skills and provide placement support for jobs in the growing sustainable energy sector! #GreenJobs #EVTraining #ElectricVehicles #Youth #Skills #training #Climate #Sustainability #SDGs #impact #drreddysfoundation

Proud to announce that we have received a royalty-free non-exclusive voluntary licence from Gilead to make the latest generation HIV drug lenacapavir accessible to patients in 120 countries! This marks an important milestone for us in patient access and affordability for pre and post exposure treatment of HIV. This collaboration with Gilead will help us make this latest treatment option available to patients in 120 primarily low- and lower- middle income countries, including India. Many of these countries have a very high disease burden of HIV, making this is an important attempt in our journey to serve over 1.5 billion patients by 2030. #WeAreDrReddys #GoodHealthCantWait #SDG3 (good health and well-being)

We are excited to welcome Peter Bartley who joins us as Head of Commercial for Consumer Healthcare. Peter will be part of our team focusing on our newly acquired global portfolio of Nicotine Replacement Therapy brands from Haleon plc, including the global market-leading brand, Nicotinell. #WeAreDrReddys #GoodHealthCantWait #DrReddysEurope #DrReddysConsumerHealthcare

Observing the birth anniversary of a great world leader, Mahatma Gandhi, who guided India towards independence through the ideals of non-violence and self-reliance. Accessible medicines is our way of contributing to the vision of peace, self-reliance and empowerment. In the year that we observed #40YearsOfDrReddys, we remember the ideals of Mahatma Gandhi with our aim to touch over 1.5 billion patients by 2030, and Indian pharma's aspiration to grow into a $400 billion industry by 2047. #GandhiJayanti #InternationalDayofNonViolence #MahatmaGandhi #GoodHealthCantWait #WeAreDrReddys

Pleased to share that we have now completed the acquisition of the Nicotine Replacement Therapy (NRT) portfolio of Haleon plc outside the United States. Our acquired portfolio consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The portfolio is inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States. Nicotinell is the second biggest brand globally (excluding the United States) in the NRT category. NRT is recommended by the ‘World Health Organization Model List of Essential Medicines’ for nicotine use disorders. The acquisition of this global portfolio of consumer healthcare products is a significant and logical extension of our efforts in consumer healthcare (nutrition and OTC wellness) in recent years, and of our purpose of ‘Good Health Can’t Wait’. We have been steadily building our OTC presence in various markets and investing in our capabilities, including a recent joint venture with Nestlé India. As a business, consumer healthcare is a growing and sustainable business with favourable long-term trends. This acquisition is an ideal anchor to continue to build our global consumer healthcare OTC business. #WeAreDrReddys #GoodHealthCantWait

Don't miss our Biologics team at Booth #24A41 from October 8th to 10th! #DrReddysBiologics #GoodHealthCantWait #WeAreDrReddys #CPHI2024

"Beekeeping and farming are inextricably linked, as bees play a crucial role in pollination, which increases the yield of crops." By integrating beekeeping with agriculture, we're boosting crop productivity and providing farmers with sustainable livelihoods. Satya Aruna, our Technical Associate for Biodiversity writes on the symbiotic relationship between bees and crops: https://lnkd.in/gsuGhkQs #Sustainability #Beekeeping #Agriculture #Farmers #Pollination #RuralLivelihoods #SDGs #DrReddysFoundation

🎤 Our CEO, Dr. Murali Ramachandra, will be presenting Aurigene Oncology Limited’s innovative approach to developing Pan-KRAS degraders at the 22nd Annual Discovery on Target conference, to be held from 🗓 Sept 30th – Oct 3rd in 📍 Boston, MA.   🔎 Leveraging our proprietary Directed Neo-substrate Degrader (DNsD) platform, the lead molecule has been optimized to effectively degrade all tested mutant KRAS proteins while maintaining exquisite selectivity over HRAS and NRAS. The nomination of the development candidate is anticipated in 🗓 Q4 2024. The conference is organized by Cambridge Healthtech Institute #BostonDOT24 #Cancer #Oncology #KRAS #PlatformTechnologies #Degraders #mutations #CancerTargets #CancerResearch #precisiononcology #OncologyTargets #OncologyPipeline #SmallMolecules #Immunooncology #DrugDiscovery #CancerTreatment #OncologyConferences #Networking #BusinessDevelopment #Partnerships #BusinessDevelopmentProfessionals #Boston #USA #Healthcare #Pharma #Pharmaceuticals

🌍 BPI Boston 2024: A Global Celebration of Biotechnology and Pharmaceutical Innovation! 🌍 This week, we had an incredible time at BPI Boston 2024, where the world's leading minds in biopharma came together to explore, innovate, and collaborate! 🌟 The conference was a dynamic platform for discussing the fascinating journey of small and large molecules from the laboratory to the market. 🔬 Key Highlights: 🖊 Insightful Sessions: Engaging talks on the latest advancements in small and large-molecule therapeutics at various stages from discovery to commercialization. 🖊 Interactive Panels: Experts shared their experiences and strategies for overcoming challenges in drug development and regulatory pathways. 🖊 Customer Engagement: We were thrilled to connect with so many of you and discuss your novel molecule needs and how we can accelerate their journey from lab to market. 🖊 Networking Opportunities: The event facilitated meaningful connections, fostering collaborations that will drive the industry forward. 🖊 A heartfelt thank you to all the attendees, speakers, and organizers for making this convention a tremendous success. Let’s continue to break new ground in biopharma together! 🚀 Now, our discovery team is gearing up for the next exciting event: Discovery on Target 2024! 🎉 Join us at Booth #424 from September 30 to October 3 at the Sheraton Boston, where we will showcase our latest advancements in biologics and small molecules. With Aurigene's comprehensive capability to support from discovery to commercial-scale cGMP manufacturing, expertise across diverse biologics modalities, and small molecule discovery in both chemistry and biology, we are well suited to taking your molecule from lab to market faster. Write to us at [email protected] to book a meeting with our experts attending the DOT conference in Boston. Meet our experts by visiting Booth #424 or drop an email to schedule a meeting. See you soon! #BPIBoston #BiotechInnovation #DrugDevelopment #Biopharma #Networking #DiscoveryOnTarget #DOT2024 #Biologics #SmallMolecules #LabToMarket #Aurigene #PharmaConference Roger Lias Jenny Yip